HALOBETASOL PROPIONATE (halobetasol propionate)

There are 0 contraindications.

There are 0 severe contraindications.

There are 2 moderate contraindications. Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.

Moderate List
Glaucoma
Hypothalamic-pituitary insufficiency

There are 15 severe adverse reactions.

More Frequent	Less Frequent
None.	Folliculitis Purpura Skin and skin structure infection Skin atrophy

Rare/Very Rare
Adrenocortical insufficiency Bullous dermatitis Cataracts Central serous chorioretinopathy Glaucoma Hypothalamic-pituitary insufficiency Ocular hypertension Skin hypopigmentation Skin striae Skin ulcer Urticaria

There are 24 less severe adverse reactions.

More Frequent	Less Frequent
Erythema Stinging of skin	Acute pain at drug application site Blurred vision Headache disorder Paresthesia Pruritus of skin Skin rash Telangiectasia Treatment site sequelae

Rare/Very Rare
Acneiform eruption Alopecia Blistering skin Contact dermatitis Dry skin Dyschromia Glycosuria Hirsutism Hypercortisolism Hyperesthesia Hyperglycemia Miliaria Perioral dermatitis Skin irritation

Safe use of topical corticosteroids during pregnancy has not been established. Although there are no adequate and controlled studies to date in humans, potent corticosteroids have been shown to be teratogenic in animals following topical application. Topical corticosteroids should be used during pregnancy only when the potential benefits justify the possible risks to the fetus. The drugs should not be used on extensive areas, in large amounts, or for prolonged periods in pregnant women.

It is not known whether topical corticosteroids are distributed into milk; however, systemic corticosteroids are distributed into milk. Topical corticosteroids should be used with caution in nursing women.

No enhanced Geriatric Use information available for this drug.